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Abstract:SH-SY5Y neural cells expressing ~a-and 8-opi-
oid receptors were maintained viable in isotonic, sodium-
free buffer in vitro. Intracellular sodium levels were manip-
ulated by various methods, and ligand binding to intact
cells was studied. In physiological buffer containing 118
mM sodium, [3H]Tyr-D-Ala-GIy-(Me) Phe-Gly-ol ([3H I-DAMGO) and [3H]naltrexonebound to ~t receptor with
KD values of 3.1 and 0.32 nM and Bmax values of 94 and
264 fmol/mg of protein, respectively. Replacement of so-
dium by choline decreased the affinity of the antagonist
and increased Bmax for [3H]DAMGO,without significantly
affecting the other corresponding binding parameters.
Depolarizing concentrations of KCI (34 mM) in physiolog-
ical buffer decreased the intracellular sodium levels by
67%, but this did not decrease the [3H]DAMGObinding
to the cells. Incubation of cells with monensin and oua-
bain increased the intracellular sodium levels dramatically
(from 78 to 250 and 300 nmol/mg, respectively), with no
changes in agonist binding parameters. Ethylisopropyl-
amiloride inhibited [3H]DAMGOand [3H]naloxonebind-
ing to intact cells with EC
50 values of 24 and 3,600 nM,
respectively. Adenylyl cyclase activities measured in in-
tact cells, at different concentrations of sodium, showed
the physiological significance of this ion in signal trans-
duction. Potency of DAMGO in inhibiting the forskolin-
stimulated adenylyl cyclase activity was significantly
higher at lowerconcentrations of sodium. However, inhi-
bition reached the maximal level only at 50 mM sodium,
and typical sigmoidal dose—response curves were ob-
tained only in the presence of 118 mM sodium. Further-
more, even at low or high intracellular sodium levels,
DAMGO inhibition of cyclic AMP levels was normal.
These results support a role for extracellular sodium in
regulating not only the ligand interactions with the recep-
tor, but also the signal transduction through the ,a recep-
tor. Key Words: Sodium—Opioid receptor—Potas-
sium—Amiloride—Monensin—Cyclic AMP.
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fists has been studied (Fischel and Medzihradsky,
1981). In many studies (e.g., Pert and Snyder, 1976),
the effective concentrations of sodium (100—150 mM)
that influenced ligand binding to opioid receptors in
isolated membranes pointed to extracellular modula-
tion by this cation. In contrast, maximal modulation
of opioid receptor binding was observed at sodium
concentrations typical for the intracellular milieu (10
mM) (e.g., Nijssen and Childers, 1987) in some stud-
ies. In 7315c cells, Puttfarcken et al. (1986) showed
an intracellular sodium site by using ligand binding to
the ~t receptor. In the course of our work on character-
ization of ligand binding to intact cells, however, we
observed that changes in intracellular levels of sodium
([Na]1) under various conditions had no effect on li-
gand binding parameters. This report thus reexamined
the site of sodium action influencing the agonist/antag-
onist binding and opioid agonist inhibition of adenylyl
cyclase activity in intact neural cells. It is particularly
important to study a homogeneous population ofrecep-
tor in view of the differential effects of sodium on ~.t,
8, and K receptors (Werling et al., 1986). Thus, all the
studies presented in this report were carried out in
SH-SY5Y cells, which express predominantly the /i
receptor, and the results were confirmed in C6~t5glial





3H]Tyr-D-Ala-Gly- (Me)Phe-Gly-ol ([3H IDAMGO; 60
Ci/mmol) was obtained from Amersham, and [3H]-
naltrexone (11 Ci/mmol) was kindly provided by the Na-
tional Institute on Drug Abuse. [3H]Naloxone (57.5 Ci!
The potent modulation of opioid receptor binding
in isolated neural membranes by sodium has been well
described (e.g., Pert et al., 1973; Simon et al., 1975),
and the mechanism by which sodium enhances the
binding of opioid antagonists and reduces that of ago-
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mmol) wasfrom New England Nuclear, and ethylisopropyl-
amiloride (EIPA) was from Research Biochemical Interna-
tional. Ouabain, monensin, DAMGO, and other biochemi-
cals were purchased from Sigma Chemical Co. Dulbecco’s
modified Eagle’s medium and fetal bovine serum were from
GIBCO Laboratories (Grand Island, NY, U.S.A.), and cyclic
AMP kits were from Diagnostic Product Corp.
Culture and treatment of cells
As described previously (Carter and Medzihradsky,
1992), human neuroblastoma SH-SY5Y cells were grown
to confluency in Dulbecco’ s modified Eagle’s medium con-
taining 10% fetal bovine serum. The confluent cells were
washed with ice-coldphosphate-buffered saline and liftedoff
the plate by incubation in Ca2~,Mg2~-free modified Puck’ssolution for 10 mm. The suspension was pelleted at 200 g
for 5 mm, thecell pellet waswashed with choline buffer, and
the resulting pellet was suspended in the respective isotonic
buffers. The basic physiological buffer (20 mM HEPES,
118 mMNaC1, 10 mMglucose, 3.0 mMMgSO
4~7H2O,1.3
mM CaC12 2H20, pH adjusted to 7.4 with Tris base at 37°C)
was modified by replacing sodium with various concentra-
tions of choline chloride in order to prepare isotonic buffers
containing 0—118 mM sodium. Buffer containing 118 mM
choline chloride has been referred to as the choline buffer
throughout the text. In experiments designed to reduce [Na],
by depolarization, retinoic acid-differentiated SH-SY5Y
cells were suspended in buffer A (128 mM NaC1, 2.4 mM
KC1, 2.0 mMNaHCO3, 3.0 mMMgSO4, 10 mMNa2HPO4,
1.3 mM CaC12, 10 mM glucose, pH 7.4 at 37°C),and 34
mM KC1 was added to induce depolarization.
Ligand binding
Ligand binding to intact cells was carried out inphysiolog-
ical buffers containing various concentrations of sodium in
different experiments as described in the legends to the fig-
ures. Nonspecific binding was determined with either 1 ~M
DAMGO or naltrexone. The assay medium consisted of 50
~il of cell suspension (SH-SY5Y, 60—120 ~.egof protein;
C6ii5, 30 ~igof protein), 50 ~.slof radiolabeled drug, 50 ~.el
each of ouabain, monensin, and EIPA (in selected experi-
ments), and 300 p~lof buffer medium. After ligand binding
reached equilibrium at 37°C(50 mm), contents of the tubes
were quickly filtered by using a Brandel cell harvester, and
the washed filters were subjected to scintillation counting.
Adenylyl cyclase assay
SH-SY5Y cells were differentiated with 10 1uM retinoic
acid for 6 days, collected, and resuspended in isotonic physi-
ological buffers containing 8 mM theophylline and 0, 5, 10,
50, and 118 mM sodium. Cells were preincubated in the
respective buffers at 37°Cfor s mm, and the acute inhibition
of adenylyl cyclase was assayed as described (Yabaluri and
Medzihradsky, 1995). In brief, the assay mixture contained
50 ~ilof cell suspension (50—100 ~.sgof protein), 20 ~l of
50 ,uMforskolin, 20 ~zlof DAMGO solution (5—5,000 nM),
and 10 ~.slof buffer. In experiments designed to increase
[Na]~, the buffer contained 118 mM sodium and 30 p~M
monensin. Cyclic AMP levels in the samples were estimated
by using the radioligand binding assay kit from Diagnostic
Product Corp.
Measurement of [Na],
Confluent cells were collected and suspended in buffers
containing various concentrations of sodium under different
experimental conditions. After incubation at 37°Cfor 50—
FIG. 1. Antagonist binding to intact SH-SY5Y cells. Cells were
washed with isotonic choline buffer and resuspended in physio-
logical buffer containing 118 mM sodium (U) or choline (s).
[
3H]Naltr xonebinding was studied at various concentrations
(0.1 —6.0 nM) as described in Materials and Methods. The corre-
sponding binding parameters and data variability are listed in
Table 1.
60 mm, samples (0.6—1.0 mg of protein) were centrifuged,
and the cell pelletwas washed three or four times with cold
choline buffer. Subsequently, the washed cell pellets were
digested in LiC1 solution (15 mEq/L) with 70% HNO
3 at
70°C.Sodium concentrations in the solutions were deter-
mined by flame photometry as described earlier (Fischel and
Medzihradsky, 1981).
Protein determination
Protein in the samples was solubilized in 1 M NaOH prior
to estimation by the method of Lowry et al. (1951), with
bovine serum albumin as the standard.
Data analysis
The binding data from saturation experiments were ana-
lyzed by the statistical program SYSTAT (Wilkinson,
1988). Dose—response curves of DAMGO-inhibited ade-
nylyl cyclase activity were fit and plotted using the nonlinear
regression program Graphpad.prism (Graph Pad Software,
San Diego, CA, U.S.A.).
RESULTS
SH-SY5Y cells were maintained viable in isotonic
buffers containing different concentrations of sodium,
the ionic strength being kept constant with the addition
of choline chloride. Saturation binding of [
3H]-
naltrexone to intact cells showed that sodium increases
the affinity of the receptor for the antagonists (Fig. 1).
The KD decreased from 0.91 ±0.12 nMto 0.32 ±0.02
nM when sodium replaced choline in the buffer, and
there was no change in the maximum number of bind-
ing sites, as the Bmax was 258 ±6.98 and 264 ±10.4
fmol/mg, respectively. The increase in affinity was
found to be gradual with respect to sodium concentra-
tion in the experiments conducted at various concentra-
tions of sodium in the assay buffer; the values are
given in Table 1.
Binding of [3H]DAMGO to whole cells was sensi-
tive to the presence of sodium in the assay buffer.
Sodium reduced the Bmax of [3H]DAMGO binding
sites as presented in Fig. 2. Analysis of the saturation
J. Neurochem., Vol. 68, No. 3, 1997
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TABLE 1. Parameters of [3H]DAMGO and [3H]naltrexone binding in intact cells
[Nal,, (mM)
0 5 10 30 118
[3H]DAMGO
K
0 (aM) 4.9 ±1.5 6.3—8.7 7.1—8.4 7.0—9.8 3.1 ±0.06




0 (nM) 0.91 ±0.12 0.51—0.57 0.40—0.42 0.44—0.45 0.32 ±0.02
Bmax (fmol/mg) 258 ±6.98 251—262 252—269 254—273 264 ±10.4
SH-SY5Y cells were suspended in isotonic physiological buffers containing various concentrations of
sodium, and binding of [
3H]DAMGO and [3H]naltrexone to whole cells was carried out as described
in Materials and Methods. Shown are means ±SEM of four or five experiments or values from two
experiments.
binding data obtained in choline buffer yielded a Bmax
of 332 ± 18 fmol/mg, whereas in the presence of
sodium it was 94 ±2.3 fmol/mg (Table 1). It is likely
that sodium converted a fraction of high-affinity sites
into the low-affinity state, because the KD increased
from a value of 4.9 ± 1.5 to 7.0—9.8 nM with the
addition of 30 mM sodium (Table 1). Previous work
carried out in our laboratory estimated a KD of ‘~ 150
nM for the low-affinity site (Carter and Medzihradsky,
1992), which cannot be detected by [3HI DAMGO in
saturation experiments. However, as multiple affinity
states are known for the receptor (Werling et al.,
1988), it is possible that DAMGO detects some popu-
lation of lower-affinity form, in addition to the high-
affinity receptor. As a result, the measured K~,a statis-
tical average of the total population, would be higher
at lower concentrations of sodium. The binding affinity
in 118 mM sodium buffers was again 3.1 ±0.06 nM,
possibly as a result of complete conversion of that
fraction of receptor sites into low-affinity form that
was rendered undetectable in saturation experiments.
These effects on binding parameters were selective for
FIG. 2. Saturation binding of [3H]DAMGOto intact cells in buff-
ers containing 118 mM sodium (s) or choline (0). Cells were
incubated with various concentrations (0.2—16 nM) of [3H]-
DAMGO at 37°Cfor 50 mm, and the radioactivity bound was
measured as described in Materials and Methods. Inset: The
displacement of [3H]DAMGO (0.6 nM) binding by naloxone (tri-
angle)and morphine(circle) in choline (open) and sodium (filled)
buffers. The experiments were repeated three or four times. The
corresponding binding parameters and data variability are listed
in Table 1.
sodium, because replacement of sodium with equimo-
lar potassium in the preliminary experiments showed
binding indistinguishable from that obtained in choline
buffer.
To examine this high-affinity binding further, [3H] -
DAMGO binding was displaced by naloxone and mor-
phine in choline and sodium buffers, and the curves
are plotted in the inset to Fig. 2. Naloxone showed
identical K
1 values of 2.3 ±0.86 nM and 2.4 ±0.66
nM, whereas morphine displaced [
3H]DAMGO with
a slightly lower K, value of 3.26 ±0.37 nM in sodium
buffer in comparison with that observed in choline
buffer (4.46 ±0.55 nM). However, these values are
not statistically significant. Initial time-dependence
studies indicated a period of 50 mm as the time re-
quired for equilibrium without any loss of specific
binding due to the internalization of the receptor.
Agonist binding was studied at various concentra-
tions of extracellular sodium ([Na ]~),and [Na]
1 was
measured in order to examine the site of sodium regu-
lation. As depicted in Fig. 3, [Na]1 dropped to 6 ±2.3
nmol/mg upon removal of sodium from the incubation
buffer and increased progressively with the addition
of sodium to the buffer. Maximal levels of [Na]1, 76
FIG. 3. Agonist binding with varying [Na]0.Cells were incubated
at 37°C in isotonic buffers containing 5—118 mM sodium and
[
3H]DAMGO(2 nM) binding, nd [Na]
1measurements were
made as described in Materials and Methods. Values are means
±SEM from six or seven experiments.
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± 3.24 nmol/mg [i.e., that may correspond to 30—
40 mM as measured by others (Motulsky and Insel,
1983)], were attained at 70—80 mM [Na]0. In con-
trast, [
3HI DAMGO binding decreased rapidly with the
inclusion of sodium (EC
50 of [Na]0, 15 mM) in the
assay buffer, and maximal inhibition was observed at
60—70mM [Na]0. Thus, [
3H]DAMGO binding curve
leveled off at 70—80 mM [Na]
0, whereas the increase
in [Na] was almost linear and 50% of the maximal
[Na]1 was obtained at 40 mM [Na]0.
Reduction in [Na],
As the inhibition of agonist binding was associated
with an increase in both [Na]0 and [Na]1, we decided
to manipulate [Na]1 by various approaches. The first
strategy was to decrease [Na] without changing [Na 10
(Fozzard and Kipnis, 1967). Intact cells were sus-
pended in physiological buffer containing 118 mM
NaC1, and 34 mM KC1 was added to decrease [Na]1.
As a result, [Na]1 dropped by >60% in comparison
with the control cells. Agonist binding was studied
under these conditions, and the results are presented
in Fig. 4. In spite of the significant reduction in [Na]1,
DAMGO binding was not altered. [Na]1 (26 ± 5.0
nmol/mg) was comparable to that obtained in the pres-
ence of 20—30 mM [Na]0, the concentrations that
should have yielded higher binding, if [Na], was re-
sponsible for the modulation of ligand binding.
Agonist binding at increased [Na]
[Na]1 could be raised by incubating the cells sus-
pended in physiological buffer containing 118 mM
sodium in the presence of Na + ,K ~-ATPase inhibitor,
ouabain (30 itM), and the sodium-specific ionophore,
monensin (30 1iM), as reported earlier (Connolly and
Limbird, 1983; Puttfarcken et al., 1986). Figure 5a
gives the details of [
3H] DAMGO binding in the pres-
enc of various (10—100 itM) concentrations of oua-
bain and monensin. Monensin and ouabain increased
[Na]
1by 3.5- and 1.5-fold over control values, respec-
tively. However, [
3H]DAMGO bi ding to intact cells
did not chang at any concentration of monensin or
ouabain. Scatchard plots of [3H]DAMGO saturation
FIG. 4. Agonist binding to intact cells in the presence of depolar-
izing concentrations of potassium. SH-SY5Y cells differentiated
with 10 bsM retinoic acid were collected and resuspended in
physiological buffers with 3.4 mM (—) or 34 mM (+) KCI. [3H]-
DAMGO binding (2 nM) (open bars) and [Na], (striped bars)
were measured as described in Materials and Methods. Values
are means ±SEM from four experiments.
FIG. 5. [3H]DAMGObinding to intact SH-SY5Y cells in physio-
logical buffers containing 118 mM sodium in the presence of
reagents that increase [Na],.a: [Na]
1(filled symbols) and [
3H]-
DAMGO binding (open symbols) were measured in the presence
of ouabain (0, • ) or monensin (A, A). Values are means ±SEM
from three experiments. b: Saturation binding of [3H]DAMGOin
the absence (0) or presence of 30 p~Mouabain (LI) or 30
1iM
monensin (A) in intact SH-SY5Y cells. The data are from a repre-
sentative experiment that was repeated three times. Inset: Ago-
nist binding in C6~i5cells, glial cells transfected with the cloned
~-opioid receptor. [
3H]DAMGO(3.2 nM) bin ing was det r-
mined in the presence of 30 .sM ouabain (o) or 30 ~.sMmonensin
(m) as described in Materials and Methods. Ouabain and monen-
sin increased [Na]~by 300 and 450% over control, respectively.
Values are means ±SEM.
isotherms obtained in the presence of 30 itM ouabain
or monensin in sodium buffer demonstrate that neither
the K~nor the Bmax was affected by the dramatic rise
in [Na], (Fig. 5b). Furthermore, in C6~t5 glial cells
that are stably transfected with the cloned i’ receptor,
ouabain (30 itM) and monensin (30 itM) enhanced
the [Na], levels by >250 and >490%, respectively,
again without any significant effect on agonist binding
(inset to Fig. 5b).
However, it is possible that monensin and ouabain
failed to show any effect on agonist binding, because
the [Na], in physiological buffers containing 118 mM
sodium was already sufficient to cause the maximal
regulation by this cation. Inhibition of agonist binding
in our experiments was found to be linear up to 20
mM [Na]
0, which corresponded to —~20nmol/mg
[Na], (Fig. 3). It was thought that any changes in [Na]1
in that range might lead to a proportional reduction in
agonist binding. In the next experiment, agonist bind-
ing to cells was studied in buffer containing 5 mM
sodium and ouabain (30 itM) or monensin (0.1 itM).
Under these conditions, [Na]1 increased from 5—6 to
23—33 nmol/mg. This [Na]1 corresponded to [Na]1 in
the presence of 30 mM [Na]0. As shown in Fig. 6,
however, binding in the presence of these two agents
was similar to that in control, whereas 30 mM sodium
in the extracellular buffer inhibited binding signifi-
cantly. Monensin is an electrically neutral antiporter
.J. Neurochem., Vol. 68, No. 3, 1997
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FIG. 6. Agonist binding in the presence of ouabain and monen-
sin at lower [Na]0.SH-SY5Y cells were collected as described in
Materials and Methods and resuspended in physiological buffers
containing 5 mM(0, •) and 30 mM (LI) sodium in the presence
(.)or absence (0) of 30 1~Mouabain and 1 fLM monensin. Cells
were incubated at 37°Cfor 50 mm with various concentrations of
[
3H]DAMGO,and binding was easured. Inset: [Na],estimated
under the same conditions. Values are means ±SEM from three
experiments.
and couples the transport of sodium with exchange of
H~or K~in a number of systems (Rochdi et al.,
1996); these neutral ionophores are also shown to
transport cations against the concentration gradients
(Harris and Pressman, 1965, and references therein).
Under the present experimental conditions, monensin
increased [Na]
1 with a simultaneous release of potas-
sium ions. At 5 mM [Na]0, in the presence of ouabain
and monensin, the intracellular potassium levels were
20—25% lower than control (223 ± 13 nmol/mg).
The next step was to study the binding in the pres-
ence of agents that are known to interact at the sodium
binding sites. Agonist and antagonist binding was stud-
ied at various concentrations of EIPA, a potent amilo-
ride analogue, and the results are presented in Fig. 7.
EIPA inhibited [
3H]DAMGO binding (143 fmol/mg)
completely with a K, value of 14.2 ±4.26 nM, and
[3H]naloxone binding (157 fmol/mg) was inhibited
with a K, value of 1.82 ± 0.337 itM.
To explore the effect of sodium further, we decided
to study the signal transduction through the it receptor.
Inhibition of adenylyl cyclase activity by DAMGO
was studied in intact cells at various concentrations
of sodium, and the results are presented in Table 2.
Forskolin-stimulated cyclic AMP levels were low in
choline buffer (15.37 ±2.02 pmol/min/mg) and were
FIG. 7. Effect of EIPA on agonist and
antagonist binding to whole cells.
Retinoic acid-differentiated SH-SY5Y
cells were incubated with various
concentrations of EIPA in choline
buffer, and [3H]DAMGObinding (4
nM; 0) and [3H]naloxonebinding (5
nM; •) were measured as described
in Materials and Methods. Values are
means ±SEM from three or four ex-
periments.
TABLE 2. DAMGO inhibition of adenylyl cyclase










0 —1.1 27 ±10.2 —
10 4.3 ±0.308 61 ±6.1 40 ±6.80
50 5.8 ±0.483 83 ±1.5 107 ±18.3
118 6.7 ±0.344” 83 ±1.7 122 ±8.70
Values are means ±SEM (n = 4). Retinoic acid-differentiated
SH-SY5Y cells were collected, washed with isotonic choline buffer,
and used to measure DAMGO inhibition of forskolin-stimulated
adenylyl cyclase activity. Cells were incubated at 37°Cfor 15 mm
in buffers containing different concentrations of sodium, and cyclic
AMP levels were estimated as described in Materials and Methods.
“p < 0.05, compared with 10 mM sodium group.
enhanced by increasing sodium concentration in the
incubation buffer, by 30—40% in buffer containing 10
mM and >100% in the presence of 118 mM NaC1
(33.4 ±4.89 pmol/min/mg). DAMGO inhibited for-
skolin-stimulated adenylyl cyclase activity in choline
buffer by 20—27% with an EC50 of 1.1 nM. Inclusion
of 50 mM sodium brought about the maximal inhibi-
tion of forskolin-stimulated adenylyl cyclase activity
by DAMGO, which was ‘-~85%under the experimental
conditions, and the sigmoidicity of the curves im-
proved with the gradual increments of sodium up to
118 mM in the assay buffer (Fig. 8). The EC50 of
attenuation of cyclic AMP levels by DAMGO in-
creased slightly with increasing sodium concentrations,
and the values obtained in buffers containing 0, 10,
and 118 mM sodium (1.1, 4.30 ± 0.308, and 6.7
±0.344 nM, respectively) were significantly different
(p < 0.05). Cyclic AMP levels were also measured
in buffer containing 34mM KC1 (i.e., under conditions
that lead to a reduction in [Na]1), but the dose—re-
sponse curves of DAMGO were not different from the
control, as the EC50 and the maximal inhibition were
6.9 ±3.25 nM and 82%, respectively. DAMGO inhibi-
tion of forskolin-stimulated cyclic AMP levels in the
presence of 30 itM monensin was comparable to con-
trol (EC5O values of 10.5 ± 1.81 nM in control, 13.9
±1.19 nM with monensin), although forskolin stimu-
lation of cyclic AMP levels increased significantly
FIG. 8. DAMGO inhibition of for-
skolin-stimulated adenylyl cyclase
activity. Intact cells were incubated
at 37°Cwith various concentrations
of DAMGO in physiological buffer
containing varying [Na]0:0 mM( •),
10 mM (0), 50 mM (A), and 118
mM (LI). KCI (34 mM) was added
to the incubation mixture to a set of
tubes (.). After 15 mm, the incuba-
tion was terminated and the cyclic AMP levels were estimated
as given in Materials and Methods. The experiment was repeated
three times, and the parameters are given in Table 2.
J. Neurochem., Vol. 68, No. 3, 1997
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FIG. 9. DAMGO inhibition of for-
skolmn-stimulated adenylyl cyclase
activity in intact cells in physiological
buffer in the absence (0)or presence
of 30 1iM monensin (LI). Adenylyl cy-
clase activity was assayed as de-
scribed in Materials and Methods.
Values are from three independent
experiments.
(53.7 ± 7.03 pmol/min/mg) (Fig. 9). Cyclic AMP
levels measured in the absence of forskolin were negli-
gible in these assays.
DISCUSSION
A number of U protein-coupled receptors are modu-
lated by sodium (Jakobs, 1979). The exact mechanism
by which sodium modulates the ligand binding, how-
ever, is not completely elucidated. Thus, the present
studies were undertaken to study the effect of sodium
chemical gradient across the neural membrane on opi-
oid receptor—ligand interactions. These modulations
are of particular significance, because the receptors are
bathed in extracellular fluids containing high concen-
trations of sodium and sodium is reported to be essen-
tial for receptor-mediated signal transduction (Blume
et al., 1979).
In the binding experiments conducted in intact cells,
agonist binding and antagonist binding were changed
differentially by sodium. Sodium-induced changes in
binding were more prominent for the agonists, leading
to =~70%reduction in the Bmax in the presence of 118
mM sodium, whereas antagonist binding showed only
an increase in the binding affinity that was not very
convenient to measure under different experimental
conditions. Hence, all the binding studies reported
herein employed DAMGO to study the effect of so-
dium on receptor—ligand interactions. Agonist binding
to cells at various concentrations of sodium suggested
that the modulation of sodium in cells was maximal
under physiological conditions. Increasing the concen-
trations of sodium in the incubation buffer progres-
sively raised [Na]1while inhibiting the agonistbinding
with an EC50 of 15 mM [Na]0 (Fig. 3).
Cellular sodium levels are regulated mainly by the
activities of Na + ,K + -ATPase and voltage-dependent
sodium channels. The sodium pump maintains a con-
stant electrochemical gradient for sodium by altering
[Na], in response to changes in membrane potential.
In the present studies, addition of depolarizing concen-
trations of potassium led to >65%reduction in cellular
sodium levels. If intracellular sodium has access to the
“sodium site” on the receptor, this depletion in sodium
levels would enhance the binding of an agonist to the
receptor. It is surprising that [
3H]DAMGO binding
was n t increa ed under these conditions, suggesting
that the receptor is rather insensitive to the changes
in [Na]
1.
In experimentsdesigned to study the agonist bin’iing
in cells with higher [Na],, at unaltered [N]0, ou~oain
and monensin wer:: added independently aUd in combi-
nation to the ph~~logical buffer. The presence of
monensin brough~:b~uta dramatic increase in [Na]1
(from 53 to 240 lU Jmg), whereas ouabain increased
[Na]1 to 120 nI’: 1mg, presumably by blocking
Na~,K~-ATPa~e:ffluxof sodium. However, the in-
creased levels ~1 NU I, in the presence of either of
these agents die ::ffect the agonist binding at all.
[
3H]DAMGO hIUhI1U measured in cells incubated in
the presence of w Sin and ouabain at the concentra-
tion range of sod U at which agonist binding would
be inhibited in a li::~:arfashion (5—10mM [Na],,) also
yielded similar results. These results show the lack
of any regulation of agonist binding by intracellular
sodium, in contrast to the earlier reports, which pro-
posed a regulatory role for intracellular sodium (Mo-
tulsky and Insel, 1983; Puttfarcken et al., 1986).
The role of sodium in the receptor-mediated ade-
nylyl cyclase activity is yet another interesting aspect
of the sodium effect. Although it was shown to be
essential for the opiate-mediated inhibition of cyclic
AMP levels (Lichtshtein et al., 1979), sodium-inde-
pendent inhibition of adenylyl cyclase activity by the
6 receptor was also reported (Isom eta!., 1987). In our
studies, DAMGO inhibited the activity of forskolin-
stimulated adenylyl cyclase by 20—27% in choline
buffer, but the maximal effect was attained only in the
presence of 50 mM sodium. The potency of DAMGO
was higher in 0 and 10 mM sodium buffers, because
the precoupled high-affinity receptor is presumably the
prevalent form in the absence of sodium (Thomsen et
al., 1988; Costa et al., 1989). The agonist potency in
inhibiting adenylyl cyclase in these studies ranged
from 1.1 to 6.8 nM, and this corresponded to the K~
obtained in binding studies, both measured in intact
cells, indicating the importance of the high-affinity
state of the receptor in signal transduction. In addition,
sodium increased the stimulation of adenylyl cyclase
activity by forskolin in these studies, whereas in
NG 108-15 cells, prostaglandin E
1 and 2-chloro-adeno-
sine stimulation of cyclic AMP levels were reported
to be normal in the absence of sodium (Lichtshtein et
a!., 1979). Forskolin is known to exert its actions di-
rectly on adenylyl cyclase, as well as through the medi-
ation of G. protein (Seamon et a!., 1981; Green and
Clark, 1982), and perhaps the direct interactions of
forskolin with the enzyme are modulated by sodium.
The dose—response curves of DAMGO at lower con-
centrations of sodium were hyperbolic, and a typical
sigmoid curve was obtained only in the presence of
buffer containing >50 mM sodium. In this respect,
the sodium effect on the system can be viewed as that
of a negative allosteric modulator that would increase
the sensitivity of a system to make it physiologically
useful. Furthermore, DAMGO attenuation of cyclic
AMP levels did not change when measured in buffers
containing 34 mM potassium (low [Na]1) or 30 itM
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monensin (high [Na]1). Thus, these results show that
signal transduction through the it receptor is also regu-
lated by extracellular sodium.
To explore the nature of the sodium effect further,
EIPA has been employed in the binding assays. Amilo-
rides, in general, are known to bind to sodium binding
sites and have been shown to interact with a2 receptors
in plasma membranes from bovine aorta in a competi-
tive, as well as noncompetitive, fashion (Jagadeesh et
al., 1990). In the same system, it was also suggested
that the allosteric effects caused by amilorides were
due to their interaction at the sodium site of action. In
the present studies, naltrexone binding was inhibited
by EIPA with a K, of 1.82 itM, which corresponds
with the K1 of 1.6 itM for the inhibition of rauwolscine
binding by EIPA in the above studies, whereas
DAMGO binding was inhibited with a K, of 14.2 nM.
This difference in the sensitivity of agonist and antago-
nist binding to EIPA corresponds closely to their so-
dium sensitivities. Sodium increased the affinity of nal-
trexone by threefold, whereas DAMGO affinity was
reduced drastically and was manifested in a reduction
in the total number of binding sites. In addition, the
results may indicate that the sodium site is located
closer to the agonist binding motif and, therefore, the
agonist binding is more sensitive to EIPA. Amilorides
have been shown to compete for the sodium binding
sites in a variety of systems (Vigne et al., 1983), and
the effects of BIPA on ligand binding to the whole
cells suggest the presence of the sodium site on the
external surface of the cell.
It is interesting that SH-SY5Y cells exhibit consider-
able high-affinity binding of DAMGO in buffers con-
taining physiological concentrations of sodium. Toll
(1992) reported DAMGO binding to a single low-
affinity site (K, of 150 nM) in intact SH-SY5Y cells,
on the basis of displacement assays using [
3H]CTOP
(3H-labeled Cys2 ,Tyr,Orn5,Pen7 amide), a peptide an-
tagonist. This could be the result of using ligand con-
centrations that were too narrow to discern two affinity
states with widely diverging KD values, because previ-
ous studies from our laboratory showed two sites with
K
1 values of 3.90 and 161 nM for DAMGO in intact
SH-SY5Y cells (Carter and Medzihradsky, 1992). In
addition, these high-affinity sites have been shown to
be coupled to the U protein, as binding to these sites
was found to be modulated by the endogenous guano-
sine triphosphate levels (Yabaluri and Medzihradsky,
1995). Furthermore, it appears that there exist two sets
of binding sites for DAMUO, because —~30%of the
sites retain their high affinity, whereas 70% of the sites
are converted into a low-affinity state in the presence
of sodium. It is possible that sodium displaces agonist
from these sites, as DAMGO can displace [
3H]-
naloxon binding completely in physiologic l buffers,
albeit at higher concentrations. Allosteric binding sites
for sodium on the receptor protein itself were first
suggested for the a
2A-adrenergic system (Michel et al.,
1980; Nunnari et a!., 1986). In addition, site-directed
mutagenesis experiments carried out on a variety of U
protein-coupled receptors, including opioid receptors,
provide important information in this regard. A highly
conserved aspartate residue in the second transmem-
brane domain of the receptors, in general, has been
shown to be important in imparting the sodium sensi-
tivity on the G110-coupled receptors (Kong et a!.,
1993a). It is interesting that this residue (Asp
95) was
implicated in th high-affinity binding of 6 receptor-
selective agonists to the cloned 6 receptor, which was
coupled to U protein and attenuated the forskolin-stim-
ulated adenylyl cyclase activity (Kong et a!., 1993b).
This might suggest that the sodium site is closer to
the agonist binding motif, as mentioned earlier in this
report. This highly conserved aspartate was identified
as a key residue in the agonist-induced receptor activa-
tion of not only the it receptor (Surratt et a!., 1994),
but also muscaninic acetylcholine receptors (Fraser et
a!., 1989), f3-adrenergic receptor (Strader et a!., 1988),
a
2A-adrenergic receptors (Wang et a!., 1991), and lu-
tropin receptor (Ji and Ji, 1991). In the present studies,
the affinity of the antagonist was improved by sodium,
whereas the number of sites was notchanged. Naltrex-
one may bind to the same set of binding sites as
DAMGO (in choline buffer), but sodium interaction
may somehow stabilize the antagonist binding, thereby
increasing the affinity. In contrast, antagonists may
bind to totally different domains and displace agonist
binding as a result of a general conformational change
(Neve et a!., 1990; Kong et a!., 1994).
The results presented in this report are contradictory
to what has been observed in 7315c cells by Putt-
farcken et al. (1986). In these cells, experiments with
monensin indicated the presence of the sodium site on
the intracellular side. In addition, it was shown that
sodium reduced the affinity of the ~ receptor without
affecting the maximal number of binding sites. The
sodium effect on agonist-receptor interactions is
known to vary for individual ligands (Pert et al.,
1973). Although the radioligand used in our studies
([
3H] D MGO) binds to the high-affinity receptor,
[3H]etorphine employed in those studies detects the
low-affinity sites. Thus, etorphine binding showed only
an increase in KD as a result of conversion of high-
affinity sites into a low-affinity form by sodium,
whereas DAMGO failed to detect the low-affinity sites
and, as a result, there was a reduction in the total
number of binding sites in saturation experiments.
However, the reasons for the differences in the experi-
ments using mor ‘snsin are not clear. The discrepancy
could be due to the fact that the 7315c cells used in
those studies were not from any stableScell line and
were obtained by dispersal of solid tumor masses. In
the present studies, the effects observed were reproduc-
ible in three cell lines, namely, undifferentiated and
retinoic acid-differentiated SH-SY5Y cells and C6it5
cells. In contrast, these differences may indicate the
importance of the ambient environment on receptor—
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ligand interactions as reported in the case of canna-
binoid receptors (Pacheco et a!., 1994).
Although an intracellular site of action was first pro-
posed in platelets (Motulsky and Insel, 1983), the re-
sults therein leave many questions unanswered. In the
same studies, although the ability of epinephrine to
attenuate prostaglandin E1-stimu!ated cyclic AMP ac-
cumulation was comparable in platelets prepared in
the presence or absence of sodium, only the platelet
aggregation was shown to be affected by the internal
pools of sodium (Connolly and Limbird, 1983). More-
over, this function was independent of U protein acti-
vation by pertussis toxin. It is possible that the mecha-
nism of action for the aggregation of platelets is en-
tirely different from the receptor-mediated attenuation
of adenylyl cyclase activity. It should also be men-
tioned that accumulation of sodium per se was shown
not to be sufficient to induce platelet aggregation
(Feinberg et a!., 1977).
Thus, the data presented in this report clearly dem-
onstrate the extracellular site of action for sodium.
[Na]1 was manipulated in both directions, and the ex-
periments with monensin, ouabain, and EIPA all point
to the regulation of ligand binding by extracellular
sodium. These studies also show the importance of
the sodium ion in signal transduction through the ~
receptor.
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